Standalone figures · ₹ crore
| ₹ Cr | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34 | 40 | 63 | 39 | 42 | 46 | 56 | 60 | 84 | 94 | 120 | 155 | |
| COGS | 8 | 16 | 23 | 14 | 16 | 17 | 21 | 24 | 34 | 35 | 55 | 65 |
| Gross profit | 27 | 24 | 40 | 25 | 26 | 30 | 35 | 36 | 50 | 58 | 65 | 90 |
| 21 | 12 | 9 | 19 | 16 | 18 | 22 | 19 | 22 | 24 | 28 | 30 | |
| 5 | 12 | 31 | 7 | 10 | 11 | 13 | 16 | 28 | 34 | 38 | 60 | |
| OPM % | 15.2% | 30.3% | 49.1% | 17% | 24.7% | 24.6% | 23.8% | 27.5% | 33.6% | 36.7% | 31.3% | 38.8% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| 2 | 1 | 3 | 5 | 6 | 4 | 5 | 5 | 6 | 11 | 12 | 2 | |
| Profit before tax | 6 | 12 | 32 | 11 | 14 | 14 | 16 | 20 | 32 | 43 | 47 | 60 |
| Tax | 1 | 3 | 8 | 2 | 4 | 3 | 4 | 5 | 8 | 10 | 11 | 16 |
| Tax % | 20.3% | 24.5% | 26.4% | 21.9% | 29.3% | 21.4% | 28% | 23.2% | 25.1% | 24.1% | 23.6% | 26.3% |
| 5 | 9 | 24 | 8 | 10 | 11 | 12 | 15 | 24 | 33 | 36 | 44 | |
| PAT margin % | 14.9% | 22.1% | 37.7% | 21.1% | 24.2% | 23.9% | 20.5% | 25.1% | 28.6% | 35.2% | 30.2% | 28.5% |
| EPS (₹) | 3.8 | 6.7 | 1.8 | 0.3 | 0.4 | 0.4 | 0.4 | 0.6 | 0.9 | 1.2 | 0.3 | 0.3 |
| Results filing | — | — | — | — | — | — | — | Results filing for Jun 2025 | Results filing for Sep 2025 | Results filing for Dec 2025 | Results filing for Mar 2026 | Results filing for Jun 2026 |
| vs same quarter last year | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % | -23.8% | -4.1% | +51.6% | +16.2% | +20.6% | +15.7% | -10.2% | +52.8% |
As reported in NSE results XBRL. Segment result is before tax and finance costs.
Latest reported period · 30 Jun 2024 · ₹ crore
| Segment | Revenue | Result | Assets | Liabilities |
|---|---|---|---|---|
| Male and Female Contraceptives & Jelly | 35.12 | 5.92 | — | 6.7 |
| Others / Unallocated | 7.32 | 4.43 | — | 18.37 |
| In Vitro Devices (IVD) | 1.59 |
| +103.2% |
| +101.7% |
| +112.4% |
| +158.7% |
| PAT YoY % | -40.3% | -11.7% | +184.4% | +282.4% | +96.1% | +25.1% | -51.3% | +81.8% | +140.2% | +196.7% | +213.9% | +194% |
| 0.21 |
| — |
| 0.31 |
₹ crore by quarter